Author

E. Trompouki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

A. Boumpas· 1 shared A. Hatzioannou· 1 shared A. Imanci· 1 shared A. Polizou· 1 shared A. Polyzou· 1 shared A. Porquet· 1 shared A. Renneville· 1 shared A. S. Papaioannou· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Boumpas

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Targeting Heterochromatin Eliminates Malignant Stem Cells in Chronic Myelomonocytic Leukemia Through Reactivation of Retroelements and Innate Immune pathways

D. Hidaoui, A. Porquet, R. Chelbi, M. Bohm, A. Polizou, V. Alcazer, S. Depil, A. Imanci, M. Morabito, A. Renneville, D. Selimoglu-Buet, S. Thepot, R. Itzykson, L. Laplane, N. Droin, , F. PORTEU

This study shows that combining DNA hypomethylating agents with H3K9me2 inhibitors reactivates immune pathways and eliminates malignant stem cells in CMML by targeting heterochromatin disorganization.

bioRxiv · Feb 2, 2024Cancer Biology

PD-L1 blockade immunotherapy rewires cancer emergency myelopoiesis

A. Boumpas, A. S. Papaioannou, P. Bousounis, M. Grigoriou, V. Bergo, I. Papafragkos, A. Tasis, M. Iskas, L. Boon, M. Makridakis, A. Vlahou, E. Gavriilaki, A. Hatzioannou, I. Mitroulis, E. Trompouki, P. Verginis

This study shows PD-L1 blockade in tumor-bearing mice targets bone marrow HSPCs, reprograms their transcriptome toward inflammation, and reduces myeloid-derived suppressor cells.

bioRxiv · Dec 20, 2023 · PreprintImmunology

ADA2 is a lysosomal DNase regulating the type-I interferon response

O. K. Greiner-Tollersrud, M. Krausz, E. Bartok, V. Boehler, H. Ebersbach, S. Baash, D. Guerini, G. Hartmann, K. Huebscher, G. Kochs, M. Marchant, A. Polyzou, J. Schepp, M. Seidl, C. R. Smulski, , M. Proietti

The paper identifies ADA2 as a lysosomal DNase that regulates the type-I interferon response by degrading cGAS/Sting-activating ligands in DADA2 patients.

bioRxiv · Jun 21, 2020 · PreprintImmunology